Highest-materiality recent filing
Revelation Biosciences Q1 net loss $3.0M; cash $14.1M; FDA agrees to adaptive Phase 2/3 study
Net loss $3.0M ($2.71/share) vs $2.1M ($25.34/share) in Q1 2025; operating cash burn $3.2M.
Stockholders approved issuance of shares exceeding 20% of outstanding (For 4,033,345, Against 104,162, Abstain 34,228).
Revelation Biosciences reports Q4 and FY2025 results; cash $10.7M, net loss $8.9M
Cash and cash equivalents $10.7M as of Dec 31, 2025 vs $6.5M in 2024; net proceeds of $6.7M from warrant inducement in January 2026
Revelation Biosciences raises ~$7.3M via warrant exercise; issues new warrants
Two holders exercised 8,544,999 pre-split Class I warrants at $0.86/share, gross proceeds ~$7.3M.
Revelation Biosciences reaches FDA agreement on approval pathway for Gemini AKI treatment
FDA agreed single Phase 2/3 adaptive study (~300 patients) can support NDA for Gemini in AKI.
Revelation Biosciences reports positive Phase 1b Gemini results; plans Phase 2/3 AKI study in 2026
Phase 1b CKD study completed with positive results; Gemini rebalances inflammation at cellular level.
Revelation Biosciences Q3 net loss $1.9M, cash $12.7M; cash runway through Q3 2026
Net loss for Q3 2025 was $1.9M ($1.77 per share) vs $2.2M ($40.15) in Q3 2024.
Special Meeting of Stockholders canceled due to technical difficulty preventing all shares from being voted.
Revelation Biosciences adjourns Oct 15 special meeting to Oct 29 due to no quorum
Special Meeting adjourned because insufficient shares were present to form a quorum.
Revelation Biosciences raises $9.6M via immediate exercise of existing warrants
$9.6M gross proceeds from exercise of 13,065,000 existing warrants at $2.20/share.
Gemini met primary safety endpoint; well-tolerated at target dose with only mild Grade I events.
Revelation Biosciences Q2 net loss $2.4M; cash $5.2M; Gemini data due Q3
Net loss for Q2 2025 was $2.4M ($7.01 per share), improved from $8.4M ($246.27) in Q2 2024.
1-for-3 reverse stock split effective July 7, 2025; post-split shares ~1,534,599.
Reverse stock split authorized at ratio 1:2 to 1:250, board to set exact ratio within one year.
Revelation Biosciences closes $4M public offering of common stock and warrants
Gross proceeds ~$4M from sale of 3,640,000 shares (or pre-funded warrants) plus warrants for up to 14,560,000 shares.
Director George Tidmarsh resigns from Revelation Biosciences board to avoid conflict of interest
George Tidmarsh, MD, PhD resigned from the Board on May 23, 2025, to avoid conflict with new US governmental agency work.
On May 23, 2025, George Tidmarsh, M.D., Ph.D., resigned from the Board of Directors of Revelation Biosciences, Inc. (the “Company”).
Max materiality 0.85 · Median 0.60 · Most common event other_material